Pub Date : 2024-06-01Epub Date: 2024-05-23DOI: 10.31488/bjcr.193
Ping Zhou, Mahesh M Mansukhani, Raymond Yeh, Jiesheng Lu, Hongai Xia, Lahari Koganti, Jiuhong Pang, Denis Toskic, Stephanie Scalia, Xun Ma, Nancy Coady Lyons, Teresa Fogaren, Cindy Varga, Raymond L Comenzo
Background: Early diagnosis of systemic light-chain amyloidosis (AL) is needed because 25% of patients die within months of diagnosis. In patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) of the λ isotype, we explored the use of 2 screening variables: a free light chain difference of 23mg/L between λ and k and presence of IGLV genes that occur more frequently in AL.
Methods: Patients contacted us and we sent HIPAA release and consent forms for discussion by phone. Their physicians were not involved. We enrolled patients with λ MGUS or SMM who met the FLC criteria with no prior biopsies showing amyloid. They sent us blood or marrow specimens for IGLV gene amplification by RT-PCR; we also assessed the feasibility of next generation sequencing (NGS) for IGLV genes. We informed patients and their physicians of results suggesting further evaluation for AL.
Results: We enrolled 21 patients, 19 SMM and 2 MGUS, receiving blood (n=21) or marrow (n=5) specimens. We identified IGLV genes in 86% (18/21) of cases. Four of the 18 IGLV genes were not AL-related and 3 of these 4 progressed to myeloma requiring therapy; the 4th was screened for amyloid and was negative. Fourteen patients with AL-related genes had comprehensive evaluations and two with SMM had AL. RT-PCR and NGS identified the AL-related LV2-14 in those two and also the monoclonal IGLV genes from all of the marrow but not the peripheral blood samples.
Conclusion: We concluded that these variables may be useful in screening for AL in λ MGUS and SMM patients and acquired support for a small multi-center study employing marrow samples only.
{"title":"Seeking Amyloidosis Very Early: Free light Chain Differentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal Gammopathies.","authors":"Ping Zhou, Mahesh M Mansukhani, Raymond Yeh, Jiesheng Lu, Hongai Xia, Lahari Koganti, Jiuhong Pang, Denis Toskic, Stephanie Scalia, Xun Ma, Nancy Coady Lyons, Teresa Fogaren, Cindy Varga, Raymond L Comenzo","doi":"10.31488/bjcr.193","DOIUrl":"10.31488/bjcr.193","url":null,"abstract":"<p><strong>Background: </strong>Early diagnosis of systemic light-chain amyloidosis (AL) is needed because 25% of patients die within months of diagnosis. In patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) of the λ isotype, we explored the use of 2 screening variables: a free light chain difference of 23mg/L between λ and k and presence of IGLV genes that occur more frequently in AL.</p><p><strong>Methods: </strong>Patients contacted us and we sent HIPAA release and consent forms for discussion by phone. Their physicians were not involved. We enrolled patients with λ MGUS or SMM who met the FLC criteria with no prior biopsies showing amyloid. They sent us blood or marrow specimens for IGLV gene amplification by RT-PCR; we also assessed the feasibility of next generation sequencing (NGS) for IGLV genes. We informed patients and their physicians of results suggesting further evaluation for AL.</p><p><strong>Results: </strong>We enrolled 21 patients, 19 SMM and 2 MGUS, receiving blood (n=21) or marrow (n=5) specimens. We identified IGLV genes in 86% (18/21) of cases. Four of the 18 IGLV genes were not AL-related and 3 of these 4 progressed to myeloma requiring therapy; the 4th was screened for amyloid and was negative. Fourteen patients with AL-related genes had comprehensive evaluations and two with SMM had AL. RT-PCR and NGS identified the AL-related LV2-14 in those two and also the monoclonal IGLV genes from all of the marrow but not the peripheral blood samples.</p><p><strong>Conclusion: </strong>We concluded that these variables may be useful in screening for AL in λ MGUS and SMM patients and acquired support for a small multi-center study employing marrow samples only.</p>","PeriodicalId":520368,"journal":{"name":"British journal of cancer research","volume":"7 2","pages":"681-686"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号